Ebronucimab vs Tafolecimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Ebronucimab
Marketed by Hubei Jumpcan Pharmaceutical and partners
NCT05255094 · Phase 3 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 464 participants, providing a strong experimental design. Its primary endpoint was a laboratory lipid measure rather than a hard clinical outcome. The registry record gives no statistical test for the primary comparison; the key result shown reports it from the cited source.
Reported efficacy
Percentage change from baseline of serum LDL-C level (At week 12): LDL-C percentage change from baseline to week 12 vs placebo: 450 mg Q4W -59.13 percentage points (95% CI -64.10 to -54.15, adjusted p<0.0001); 150 mg Q2W -60.43 percentage points (95% CI -65.45 to -55.416, adjusted p<0.0001). (met)
Result source: NCT05255094
Tafolecimab · Sintbilo
Marketed by Innovent Biologics
NCT04289285 · Phase 3 · completed
This randomised, quadruple-blind, placebo-controlled trial randomised 618 Chinese patients with non-familial hypercholesterolaemia (614 dosed) and met its primary endpoint: LDL cholesterol fell 57 to 65 percentage points more than with placebo at week 48 across both dosing regimens, a highly statistically significant result.
618 patients were randomised (publication); the registry's actual-enrolment field says 804.
Next expected readout: December 2026 · NCT07341958 (registry estimate)
Reported efficacy
Mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at week 48: LDL-C percent change from baseline to week 48, treatment difference vs placebo: -65.0% (97.5% CI: -70.2%, -59.9%) for tafolecimab 450 mg Q4W; -57.3% (97.5% CI: -64.0%, -50.7%) for 600 mg Q6W; both P < 0.0001 (met)
Result source: NCT04289285
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ebronucimab | Tafolecimab |
|---|---|---|
| LDL-C, % change | —Not posted · NCT05260411 | -58.7% vs 3.2%a−61.9 vs placeboNCT041796692 other results
|
| Non-HDL-C, % change | —Not posted · NCT05260411 | —Not posted · NCT04031742 |
| ApoB, % change | —Not posted · NCT05260411 | —Not posted · NCT04031742 |
| Lp(a), % change | —Not posted · NCT05260411 | —Not posted · NCT04031742 |
| 3-point MACE (% with event) | —Not posted · NCT05260411 | —Not posted · NCT04031742 |
LDL-C, % change
- Ebronucimab
- —Not posted · NCT05260411
- Tafolecimab
- -58.7% vs 3.2%a−61.9 vs placeboNCT04179669
2 other results
- -58.4% vs -1% NCT04179669
- -68.9% vs -5.8% NCT04709536
Non-HDL-C, % change
- Ebronucimab
- —Not posted · NCT05260411
- Tafolecimab
- —Not posted · NCT04031742
ApoB, % change
- Ebronucimab
- —Not posted · NCT05260411
- Tafolecimab
- —Not posted · NCT04031742
Lp(a), % change
- Ebronucimab
- —Not posted · NCT05260411
- Tafolecimab
- —Not posted · NCT04031742
3-point MACE (% with event)
- Ebronucimab
- —Not posted · NCT05260411
- Tafolecimab
- —Not posted · NCT04031742
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ebronucimab
show 1 more result
Tafolecimab
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ebronucimab's landscape · Tafolecimab's landscape